Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
A realistic timeline, based on where the Phase 3 programme is now, looks like this: FDA submission in the U.S.: late 2026 or 2027 FDA approval: 2027 or 2028 UK MHRA review: typically 12 to 24 months after FDA approval NHS access through a NICE appraisal: a separate process, usually 12 to 24 months after MHRA approval The earliest UK private access through online pharmacies, mirroring how Mounjaro and Wegovy first launched here, is likely 2027 or 2028
Weight loss injections, such as those containing GLP-1 agonists like semaglutide, work by mimicking the GLP-1 hormone, which helps regulate appetite and blood sugar levels
Efpeglenatide is a long-acting GLP-1RA, which was developed for the management of hyperglycemia in patients with T2D [50]
Bioorthogonal activation of dual catalytic and anti-cancer activities of organogold(I) complexes in living systems
.png)
